1. Home
  2. GLBE vs CINGW Comparison

GLBE vs CINGW Comparison

Compare GLBE & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLBE
  • CINGW
  • Stock Information
  • Founded
  • GLBE 2013
  • CINGW N/A
  • Country
  • GLBE Israel
  • CINGW United States
  • Employees
  • GLBE N/A
  • CINGW 13
  • Industry
  • GLBE Computer Software: Prepackaged Software
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GLBE Technology
  • CINGW Health Care
  • Exchange
  • GLBE Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • GLBE N/A
  • CINGW N/A
  • IPO Year
  • GLBE 2021
  • CINGW 2021
  • Fundamental
  • Price
  • GLBE $41.35
  • CINGW $0.05
  • Analyst Decision
  • GLBE Strong Buy
  • CINGW
  • Analyst Count
  • GLBE 12
  • CINGW 0
  • Target Price
  • GLBE $42.83
  • CINGW N/A
  • AVG Volume (30 Days)
  • GLBE 847.3K
  • CINGW N/A
  • Earning Date
  • GLBE 11-20-2024
  • CINGW N/A
  • Dividend Yield
  • GLBE N/A
  • CINGW N/A
  • EPS Growth
  • GLBE N/A
  • CINGW N/A
  • EPS
  • GLBE N/A
  • CINGW N/A
  • Revenue
  • GLBE $632,887,000.00
  • CINGW N/A
  • Revenue This Year
  • GLBE $30.70
  • CINGW N/A
  • Revenue Next Year
  • GLBE $29.87
  • CINGW N/A
  • P/E Ratio
  • GLBE N/A
  • CINGW N/A
  • Revenue Growth
  • GLBE 27.51
  • CINGW N/A
  • 52 Week Low
  • GLBE $28.11
  • CINGW N/A
  • 52 Week High
  • GLBE $43.52
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GLBE 65.67
  • CINGW N/A
  • Support Level
  • GLBE $39.11
  • CINGW N/A
  • Resistance Level
  • GLBE $43.52
  • CINGW N/A
  • Average True Range (ATR)
  • GLBE 1.00
  • CINGW 0.00
  • MACD
  • GLBE 0.29
  • CINGW 0.00
  • Stochastic Oscillator
  • GLBE 66.50
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: